Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD

Clin J Am Soc Nephrol. 2023 May 1;18(5):557-559. doi: 10.2215/CJN.0000000000000148. Epub 2023 Apr 7.

Authors

Ayodele Odutayo^{1

2}, Adeera Levin^{1

2

3}

Affiliations

¹ Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
² Division of Cardiology, Women's College Hospital, Toronto, Ontario, Canada.
³ British Columbia Provincial Renal Agency, Vancouver, British Columbia, Canada.

No abstract available

Publication types

Editorial

MeSH terms

Female
Humans
Male
Renal Insufficiency, Chronic*
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors